IMAC Holdings, Inc. Announces Initiation of Third and Final Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
March 24, 2022 08:00 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, March 24, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has initiated the third and final cohort of its Phase 1 clinical...
IMAC Holdings, Inc. Announces Initiation of Second Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
July 13, 2021 09:00 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, July 13, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has initiated the second cohort of its Phase 1 clinical trial for...
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
March 01, 2021 09:25 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for...